Weekly Promotions

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

The 10 Key Lab Tests to Review with Your Doctor™ panel contains 17 tests with 78 biomarkers. 

1. Apolipoprotein B, Cardio IQ
2. C-Reactive Protein (CRP) 
3. CBC (includes Differential and Platelets) 
4. Hemoglobin A1c, Cardio IQ™
5. hs-CRP, Cardio IQ™
6. Lipid Panel, Cardio IQ™
7. QuestAssureD™ 25-Hydroxyvitamin D (D2, D3)
8. TSH, Free T3 and Free T4 Blood Test Panel
9. Ferritin, Iron & Total Iron Binding Capacity -TIBC
10. BCA Chemistry Panel
    • Gamma Glutamyl Transferase (GGT) 
    • Comprehensive Metabolic Panel (CMP)
    • Lactate Dehydrogenase (LD) 
    • Phosphate (as Phosphorus) 
    • Uric Acid
    • Glucose
    • Magnesium

Lactate Dehydrogenase (LD) (LDH)

Elevations in serum lactate dehydrogenase occur from myocardial infarction, liver disease, pernicious and megaloblastic anemia, pulmonary emboli, malignancies, and muscular dystrophy

For diagnosis of hypothyroidism and hyperthyroidism.

Note: Free T4 Index (T7) will only be calculated and reported if test code code 861 (T3 Uptake) is ordered as well.

This test is useful in the differential diagnosis of male hypogonadism. For males 18 years of age and older only.

Dipstick urinalysis is important in accessing the chemical constituents in the urine and the relationship to various disease states. Microscopic examination helps to detect the presence of cells and other formed elements.

Useful in the diagnosis of hypochromic, microcytic anemias. Decreased in iron deficiency anemia and increased in iron overload.

Cardio IQ® ASCVD Risk Panel with Score 

This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history. 
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Active Lifestyle
• Conditioning
• Endurance
• Overall Health
• Performance
• Strength Training
• Weight Loss

The Blueprint Fitness - Baseline Insights Panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin - Globulin Ratio 
4. Alkaline Phosphatase 
5. Aspartate Aminotransferase (AST) 
6. Basophils 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. Calcium 
10. Carbon Dioxide (CO2) 
11. Chloride 
12. Cholesterol 
13. Cholesterol - High Density Lipoprotein (HDL) Ratio 
14. Corpuscular Volume (MCV) 
15. Cortisol 
16. Creatinine 
17. Eosinophils 
18. Estimated Glomerular Filtration Rate (eGFR) 
19. Gamma Glutamyl Transferase (GGT) 
20. Globulin 
21. Glucose 
22. Hematocrit 
23. Hemoglobin (HGB) 
24. Hemoglobin A1c 
25. High Density Lipoprotein (HDL) 
26. Low Density Lipoprotein (LDL) 
27. Lymphocytes 
28. Mean Corpuscular Hemoglobin (MCH) 
29. Mean Corpuscular Hemoglobin Concentration (MCHC) 
30. Mean Platelet Volume (MPV) 
31. Monocytes 
32. Neutrophils 
33. Non-HDL Cholesterol 
34. Platelet Count (PLT) 
35. Potassium 
36. Protein 
37. Red Blood Cell Distribution Width (RDW) 
38. Red Blood Cells 
39. Sodium 
40. Triglycerides 
41. Urea Nitrogen (BUN) 
42. Uric Acid
43. Vitamin D, 25-OH, D2
44. Vitamin D, 25-OH, D3
45. Vitamin D, 25-OH, TOTAL
46. White Blood Cells 

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Body Composition
• Fat Burning
• Overall Health
• Weight Loss
• Weight Management

The Blueprint Fitness - Metabolic Performance panel contains the following biomarkers.

1. C-Reactive Protein (hs-CRP) 
2. Carotene 
3. Cholesterol 
4. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
5. Cortisol 
6. Estrogen 
7. Fructosamine
8. Glucose 
9. Hemoglobin A1c 
10. High-Density Lipoprotein (HDL) 
11. Insulin 
12. Low-Density Lipoprotein (LDL) 
13. Non-HDL Cholesterol 
14. Sex hormone binding globulin
15. Testosterone
16. Testosterone.free
17. Triglycerides 
18. Vitamin D, 25-OH, D2
19. Vitamin D, 25-OH, D3
20. Vitamin D, 25-OH, TOTAL
21. Vitamin E
     

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Anabolic Optimization
• Endurance Training
• Functional Fitness
• Recovery
• Strength Training

The Blueprint Fitness  - Training Status panel contains the following biomarkers.

1. C-Reactive Protein (hs-CRP) 
2. Cortisol 
3. Creatine Kinase (CK) 
4. Immunoglobulin A (IgA) 
5. Iron 
6. Percent (%) Saturation 
7. Sex hormone binding globulin
8. Testosterone
9. Testosterone - Cortisol (T-C) Ratio 
10. Testosterone.free
11. Thyroid Stimulating Hormone (TSH) 
12. Total Iron Binding Capacity (TIBC)
13. Transferrin 

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Aerobic Optimization
• Altitude Training
• Cardiovascular Health
• Conditioning
• Distance Training
• Endurance Training
• Hydration
• Speed Training

Blueprint Fitness - Endurance & Conditioning panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Aspartate Aminotransferase (AST) 
6. Basophils 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. Calcium 
10. Carbon Dioxide (CO2) 
11. Chloride 
12. Corpuscular Volume (MCV) 
13. Creatinine 
14. Eosinophils 
15. Estimated Glomerular Filtration Rate (eGFR) 
16. Ferritin 
17. Folate (Folic Acid) 
18. Globulin 
19. Glucose 
20. Hematocrit 
21. Hemoglobin (HGB) 
22. Iron 
23. Lactate Dehydrogenase (LD) 
24. Lymphocytes 
25. Mean Corpuscular Hemoglobin (MCH) 
26. Mean Corpuscular Hemoglobin Concentration (MCHC) 
27. Mean Platelet Volume (MPV) 
28. Monocytes 
29. Neutrophils 
30. Percent (%) Saturation 
31. Platelet Count (PLT) 
32. Potassium 
33. Protein 
34. Red Blood Cell Distribution Width (RDW) 
35. Red Blood Cells 
36. Sodium 
37. Total Iron Binding Capacity (TIBC) 
38. Transferrin 
39. Urea Nitrogen (BUN) 
40. Vitamin B12 
41. White Blood Cells 

Excellent For:

• Active Lifestyle
• Body Composition
• Diet
• Endurance Training
• Fueling
• Muscle Building
• Overall Health
• Strength Training
• Weight Loss

Blueprint Fitness - Nutrition panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Arachidonic Acid (AA) 
6. Aspartate Aminotransferase (AST) 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. Calcium 
10. Carbon Dioxide (CO2) 
11. Carotene 
12. Chloride 
13. Cholesterol 
14. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
15. Creatinine 
16. Docosahexaenoic Acid (DHA) 
17. Eicosapentaenoic Acid (EPA) 
18. EPA - Arachidonic Acid Ratio 
19. Estimated Glomerular Filtration Rate (eGFR) 
20. Ferritin 
21. Folate (Folic Acid) 
22. Fructosamine
23. Globulin 
24. Glucose 
25. Hemoglobin A1c 
26. High-Density Lipoprotein (HDL) 
27. Iron 
28. Low-Density Lipoprotein (LDL) 
29. Mercury 
30. Non-HDL Cholesterol 
31. Omega-3 
32. Omega-6 
33. Percent (%) Saturation 
34. Potassium 
35. Protein 
36. Sodium 
37. Total Iron Binding Capacity (TIBC) 
38. Triglycerides 
39. Urea Nitrogen (BUN) 
40. Vitamin B12 
41. Vitamin D, 25-OH, D2
42. Vitamin D, 25-OH, D3
43. Vitamin D, 25-OH, TOTAL
44. Vitamin E

his panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Excellent For:

• Aerobic Optimization
• Anabolic Optimization
• Body Composition
• Endurance Training
• Muscle Building
• Overall Health
• Strength Training

Weight Management

Blueprint Fitness - Hormones panel contains the following biomarkers.

1. Cortisol 
2. Estradiol
3. Progesterone 
4. Sex hormone binding globulin
5. Testosterone
6. Testosterone - Cortisol (T-C) Ratio 
7. Testosterone.free

Blueprint Fitness - Endurance-Metabolic-Training 3  panel combines three Blueprint Fitness panels ( Metabolic Performance, Training Status, and Endurance & Conditioning)

Excellent For:

• Aerobic Optimization
• Altitude Training
• Anabolic Optimization
• Body Composition
• Cardiovascular Health
• Conditioning
• Distance Training
• Endurance Training
• Fat Burning
• Functional Fitness
• Hydration
• Overall Health
• Recovery
• Speed Training
• Strength Training
• Weight Loss
• Weight Management

Blueprint Fitness - Endurance-Metabolic-Training 3  panel combines three Blueprint Fitness panels ( Metabolic Performance, Training Status, and Endurance & Conditioning) This panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Aspartate Aminotransferase (AST) 
6. Basophils 
7. Bilirubin 
8. BUN - Creatinine Ratio 
9. C-Reactive Protein (hs-CRP) 
10. Calcium 
11. Carbon Dioxide (CO2) 
12. Carotene 
13. Chloride 
14. Cholesterol 
15. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
16. Corpuscular Volume (MCV) 
17. Cortisol 
18. Creatine Kinase (CK) 
19. Creatinine 
20. Eosinophils 
21. Estimated Glomerular Filtration Rate (eGFR) 
22. Estrogen 
23. Ferritin 
24. Folate (Folic Acid) 
25. Fructosamine
26. Globulin 
27. Glucose 
28. Glucose 
29. Hematocrit 
30. Hemoglobin (HGB) 
31. Hemoglobin A1c 
32. High-Density Lipoprotein (HDL) 
33. Immunoglobulin A (IgA) 
34. Insulin 
35. Iron 
36. Lactate Dehydrogenase (LD) 
37. Low-Density Lipoprotein (LDL) 
38. Lymphocytes 
39. Mean Corpuscular Hemoglobin (MCH) 
40. Mean Corpuscular Hemoglobin Concentration (MCHC) 
41. Mean Platelet Volume (MPV) 
42. Monocytes 
43. Neutrophils 
44. Non-HDL Cholesterol 
45. Percent (%) Saturation 
46. Platelet Count (PLT) 
47. Potassium 
48. Protein 
49. Red Blood Cell Distribution Width (RDW) 
50. Red Blood Cells 
51. Sex hormone binding globulin
52. Sodium 
53. Testosterone
54. Testosterone.free
55. Thyroid Stimulating Hormone (TSH) 
56. Total Iron Binding Capacity (TIBC)
57. Total Iron Binding Capacity (TIBC) 
58. Transferrin 
59. Triglycerides 
60. Urea Nitrogen (BUN) 
61. Vitamin B12 
62. Vitamin D, 25-OH, D2
63. Vitamin D, 25-OH, D3
64. Vitamin D, 25-OH, TOTAL
65. Vitamin E
66. White Blood Cells 

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Blueprint Fitness - 2 Baseline-Nutrition-Hormones panel combines three Blueprint Fitness panels ( Baseline Insights, Training Status, Nutrition, and Hormones). 

Excellent For:

• Active Lifestyle
• Aerobic Optimization
• Anabolic Optimization
• Body Composition
• Conditioning
• Diet
• Endurance
• Endurance Training
• Fueling
• Muscle Building
• Overall Health
• Performance
• Strength Training
• Weight Loss
• Weight Management

Blueprint Fitness - 2 Baseline-Nutrition-Hormones panel combines three Blueprint Fitness panels ( Baseline Insights, Training Status, Nutrition, and Hormones). 

This panel contains the following biomarkers.

1. Alanine Aminotransferase (ALT) 
2. Albumin 
3. Albumin-Globulin Ratio 
4. Alkaline Phosphatase 
5. Arachidonic Acid (AA) 
6. Aspartate Aminotransferase (AST) 
7. Basophils 
8. Bilirubin 
9. BUN - Creatinine Ratio 
10. Calcium 
11. Carbon Dioxide (CO2) 
12. Carotene 
13. Chloride 
14. Cholesterol 
15. Cholesterol - High-Density Lipoprotein (HDL) Ratio 
16. Corpuscular Volume (MCV) 
17. Cortisol 
18. Creatinine 
19. Docosahexaenoic Acid (DHA) 
20. Eicosapentaenoic Acid (EPA) 
21. Eosinophils 
22. EPA - Arachidonic Acid Ratio 
23. Estimated Glomerular Filtration Rate (eGFR) 
24. Estradiol
25. Ferritin 
26. Folate (Folic Acid) 
27. Fructosamine
28. Gamma Glutamyl Transferase (GGT) 
29. Globulin 
30. Glucose 
31. Hematocrit 
32. Hemoglobin (HGB) 
33. Hemoglobin A1c 
34. High-Density Lipoprotein (HDL) 
35. Iron 
36. Low-Density Lipoprotein (LDL) 
37. Lymphocytes 
38. Mean Corpuscular Hemoglobin (MCH) 
39. Mean Corpuscular Hemoglobin Concentration (MCHC) 
40. Mean Platelet Volume (MPV) 
41. Mercury 
42. Monocytes 
43. Neutrophils 
44. Non-HDL Cholesterol 
45. Omega-3 
46. Omega-6 
47. Percent (%) Saturation 
48. Platelet Count (PLT) 
49. Potassium 
50. Progesterone 
51. Protein 
52. Red Blood Cell Distribution Width (RDW) 
53. Red Blood Cells 
54. Sex hormone binding globulin
55. Sodium 
56. Testosterone
57. Testosterone.free
58. Total Iron Binding Capacity (TIBC) 
59. Triglycerides 
60. Urea Nitrogen (BUN) 
61. Uric Acid
62. Vitamin B12 
63. Vitamin D, 25-OH, D2
64. Vitamin D, 25-OH, D3
65. Vitamin D, 25-OH, TOTAL
66. Vitamin E
67. White Blood Cells

This panel also provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Celiac Disease - Advanced panel contained 12 tests and 70 biomarkers.

*Please note the Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

IMPORTANT - Celiac Disease Comprehensive Panel #19955 contains reflex tests - which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive,

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Specimens from children less than 4 years of age (i.e., less than 48 months) are appropriate for this test. The test for people 4 years of age and older is the Celiac Disease Comprehensive Panel (test code 19955).

TISSUE TRANSGLUTAMINASE AB, IGA
IMMUNOGLOBULIN A
GLIADIN (DEAMIDATED) AB (IGA)

Clinical Significance

This panel assists in differentiating celiac disease from other inflammatory bowel diseases and helps avoid progression of celiac disease, particularly in children, through early identification of gluten sensitivity.

Alternative Name(s) 

Tissue Transglutaminase (tTG),Gluten Sensitivity, tTG, EMA,Gliadin Antibody

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

MMR (IgG) Panel (Measles, Mumps, Rubella) Titers - Includes Measles Antibody (IgG), Mumps Antibody (IgG), Rubella Immune Status

This panel provides presumptive evidence of immunity to measles, mumps, and rubella for purposes of routine vaccination, for students at post-high school educational institutions, and for international travelers.

Varicella-Zoster Virus (VZV) causes chicken pox and when reactivated, potentially decades later, causes shingles. Twenty percent of adults will develop shingles, a rash or blister of the skin that may cause severe pain. Varicella-Zoster IgG, EIA reliably measures immunity due to previous infection, but is unsuitable for detection of post-vaccination immune status.

The Varicella Zoster Virus Antibodies, IgG test is typically done to check for immunity to the virus which causes chickenpox.  Varicella Zoster Virus is a member of the Herpes Virus family.  This test measures the level of antibodies produced by the immune system in response to the virus.  Results provide a numerical value for the antibody level which can be compared to a reference interval to determine immune status.  IgG antibodies are typically detectable a few weeks after the initial infection.  In the United States, many people are vaccinated against Varicella when they are young.  In most cases those who contract the virus and recover develop a natural immunity which protects them from catching it again. 

The most common condition which results from infection with Varicella is Chickenpox.  The infection causes an outbreak of an itchy rash and the development of small fluid-filled blisters.  During the primary infection, chickenpox is highly contagious and spread through coughing, sneezing or touching fluid from the blisters.  Most people recover without treatment and the virus remains latent in their system.  There is a possibility for the virus to reactivate later in life, especially in those with weakened immune systems.  This can cause shingles, a condition characterized by a painful burning or itching sensation on one or more areas of the body.  Shingles typically clear up after a few weeks as the virus becomes latent again.

The Varicella IgG Antibody Titer is usually ordered when someone is required to show proof of immune status for work or school.  It may also be done for organ transplant patients or pregnant women.

The Varicella Titer is also available as part of our Immunity Panel which includes other common titer tests.

Tetanus Antitoxoid (Titer)

Clinical Significance

Tetanus is caused by Clostridium tetani. Immunization with Tetanus Antitoxoid is effective with boosters in immunocompetent individuals. Antibody levels > or = to 0.10 IU/mL are considered protective. However, tetanus can still occur in some individuals with such antibody levels. These results should not be used to determine the necessity to administer antitoxin when clinically indicated. For Pre and Post vaccination testing to assess normal immune response, please refer to Test Code 91424, Tetanus Antitoxoid, Pre and Post Vaccination.

Diphtheria and Tetanus Antitoxoid (Titer)

Clinical Significance

Used to evaluate diphtheria immunization response. Antibody levels of > or = to 0.10 IU/mL are considered protective. For Pre and Post vaccination testing to assess normal immune response, please refer to Test Code 10680, Diphtheria Antitoxoid, Pre and Post Vaccination.

Tetanus is caused by Clostridium tetani. Immunization with Tetanus Antitoxoid is effective with boosters in immunocompetent individuals. Antibody levels of > or = to 0.10 IU/mL are considered protective. However, tetanus can still occur in some individuals with such antibody levels. These results should not be used to determine the necessity to administer antitoxin when clinically indicated. For Pre and Post vaccination testing to assess normal immune response, please refer to Test Code 91424, Tetanus Antitoxoid, Pre and Post Vaccination.

Diphtheria Antitoxoid (DPT Titer)

Clinical Significance

Used to evaluate diphtheria immunization response. Antibody levels of > or = to 0.10 IU/mL are considered protective. For Pre and Post vaccination testing to assess normal immune response, please refer to Test Code 10680, Diphtheria Antitoxoid, Pre and Post Vaccination.

Alternative Name(s)

DPT Titer,Anti Diphtheria

Hepatitis A & B Titer Test

• Hepatitis A Antibody, Total
• Hepatitis A IgM Antibody
• Hepatitis B Surface Antigen with Reflex Confirmation
• Hepatitis B Surface Antibody Immunity, Quantitative
• Hepatitis B Core Antibody, Total

The Hepatitis A & B Titer Test is ordered when a person needs proof of immunity to Hepatitis A and B or just want to check their immune status.

The Hepatitis Titer Test includes immunity testing for both Hepatitis A and B.  Hepatitis is a viral disease which affects the liver.  Vaccinations for Hepatitis A and B can provide protective antibodies which immunize a person from catching the virus.  Additionally, a person who has been affected by Hepatitis A or B and recovers can develop natural immunity.  Titer testing looks for the antibodies which typically indicate that a person is immune to a particular virus or infection.

Hepatitis B Immunity

Not Immune and no active or prior infection; may be a good candidate for vaccine

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Negative
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

Immunity due to vaccination

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Positive
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

HEPATITIS B INFECTION

• Hepatitis B Surface Antigen (HBsAg) = Positive  A positive result indicates an infection, usually with symptoms; contagious; could also be a flare of a chronic infection

Hepatitis A immunity

Immunity

• Hepatitis A Antibody, Total = Positive
• Hepatitis A IgM Antibody = Negative

No active infection but previous HAV exposure; has developed immunity to HAV or recently vaccinated for HAV

No Immunity

• Hepatitis A Antibody, Total= Negative
• Hepatitis A IgM Antibody = Negative

No current or previous HAV infection; vaccine may be advised if at risk

HEPATITIS A INFECTION

• Hepatitis A IgM Antibody = Positive   A positive result indicates an acute or recent infection

Hepatitis A Titer Test Panel

• Hepatitis A Antibody, Total
• Hepatitis A IgM Antibody

The Hepatitis A Titer Test is ordered when a person needs proof of immunity to Hepatitis A or just want to check their immune status.

The Hepatitis A Titer Test includes immunity testing for Hepatitis A.  Hepatitis is a viral disease which affects the liver.  Vaccinations for Hepatitis A can provide protective antibodies which immunize a person from catching the virus.  Additionally, a person who has been affected by Hepatitis A and recovers can develop natural immunity.  Titer testing looks for the antibodies which typically indicate that a person is immune to a particular virus or infection.

Hepatitis A immunity

Immunity

• Hepatitis A Antibody, Total = Positive
• Hepatitis A IgM Antibody = Negative

No active infection but previous HAV exposure; has developed immunity to HAV or recently vaccinated for HAV

No Immunity

• Hepatitis A Antibody, Total= Negative
• Hepatitis A IgM Antibody = Negative

No current or previous HAV infection; vaccine may be advised if at risk

HEPATITIS A INFECTION

• Hepatitis A IgM Antibody = Positive   A positive result indicates an acute or recent infection

Hepatitis B Titer Test

• Hepatitis B Surface Antigen with Reflex Confirmation
• Hepatitis B Surface Antibody Immunity, Quantitative
• Hepatitis B Core Antibody, Total

The Hepatitis B Titer Test is ordered when a person needs proof of immunity to Hepatitis B or just want to check their immune status.

The Hepatitis Titer Test includes immunity testing for Hepatitis B.  Hepatitis is a viral disease which affects the liver.  Vaccinations for Hepatitis B can provide protective antibodies which immunize a person from catching the virus.  Additionally, a person who has been affected by Hepatitis B and recovers can develop natural immunity.  Titer testing looks for the antibodies which typically indicate that a person is immune to a particular virus or infection.

Hepatitis B Immunity

Not Immune and no active or prior infection; may be a good candidate for vaccine

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Negative
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

Immunity due to vaccination

• Hepatitis B Surface Antigen (HBsAg) = Negative
• Hepatitis B Surface Antibody (Anti-HBs) = Positive
• Hepatitis B Core Antibody, Total (Anti-HBc IgG+IgM) = Negative

HEPATITIS B INFECTION

• Hepatitis B Surface Antigen (HBsAg) = Positive  A positive result indicates an infection, usually with symptoms; contagious; could also be a flare of a chronic infection.

Varicella-Zoster Virus Antibody (Immunity Screen), ACIF

Clinical Significance

A positive titer (≥1:4) by anticomplement immunofluorescence (ACIF) indicates a history of past infection by Varicella-Zoster virus (VZV). This antibody is usually detectable within 2 days after the onset of rash and is, thereafter, detectable for life. Conversely, the absence of detectable antibody can be used as evidence of susceptibility to varicella (chickenpox).

Immunity Panel

The Immunity Panel combines several common titer immunity tests for additional savings.  These tests are often ordered when someone needs proof of their immune status to common infectious diseases for work or school.  It may also be ordered for pregnant women as part of their prenatal testing. 

This package includes titers for: 

• Hepatitis B Surface Antibody, Quantitative
• MMR (IgG) Panel (Measles, Mumps, Rubella)
• Varicella-Zoster Virus Antibody (IgG)

For a testing package which also includes Hepatitis A, please see our Immunity Panel Plus.

Immunity Panel Plus

The Immunity Panel Plus combines several common titer immunity tests for additional savings.  These tests are often ordered when someone needs proof of their immune status to common infectious diseases for work or school.  It may also be ordered for pregnant women as part of their prenatal testing. 

This package includes titers for:

• Hepatitis A Antibody, Total
• Hepatitis B Surface Antibody, Quantitative
• MMR (IgG) Panel (Measles, Mumps, Rubella)
• Varicella-Zoster Virus Antibody (IgG)

Please note that the Hepatitis A Total Antibodies test included in this package does not provide numerical results.  Results for this test will be positive or negative only.

Tuberculosis (TB) Test - The QuantiFERON-TB Blood Test is used to aid in the diagnosis of both latent and active infections with the bacteria that causes Tuberculosis (TB). This test has been updated to offer the Quantiferon Gold Plus which has the same high level of specificity as the previous generation of testing along with an increased sensitivity of 94%.  This test is one of only 2 blood tests for TB approved by the FDA.  Tuberculosis is a bacterial disease that typically affects the lungs.  TB Bacteria is spread through the air from one person to another. While TB is not as common in the United States as it once was, there is the still a risk posed by TB infection.  It is estimated that 11 million people in the US have a latent Tuberculosis infection (LTBI).

Tuberculosis is a communicable disease caused by infection with M. tuberculosis complex. Infection results in either acute disease or Latent TB Infection (LTBI), a non-communicable asymptomatic condition. The main purpose of diagnosing the latent stage is to consider medical treatment for preventing overt disease. Until recently, the tuberculin skin test was the only available method for diagnosing LTBI.

QuantiFERON®-TB gold eliminates false positive skin test due to BCG vaccination and most Non-Tuberculous Mycobacteria (NTM) and is an objective, reproducible qualitative test. There are no side effects or adverse reactions due to patient hypersensitivity, and no "booster effect", whereby the first test induces a false positive response on re-testing. There is no need for follow-up patient visits to obtain test results.

The TB blood test has several advantages over a skin test.  Blood testing requires only one visit to the lab while skin testing requires multiple visits to a doctor's office.  Blood testing for Tuberculosis is typically more accurate than a skin test.  Skin testing has a higher likelihood of false positive results, especially if a person has been previously vaccinated for TB.